By Fineline Cube Boya Biological Pharmacy Co., Ltd., (SHE: 300294) a China-based pharmaceutical company, has agreed to divest 100% equity of Nanjing Xinbai Pharmaceutical Co., Ltd. to China Resources Double-Crane Pharmaceutical Co., Ltd. (CR Double-Crane) for RMB 235.5 million (approximately USD 34.4 million).
The transaction marks a strategic portfolio realignment for Boya Biological and bolsters CR Double-Crane’s position in the hospital-focused injectables segment, particularly in lyophilized powder injections and small-volume parenterals—key dosage forms in China’s acute care settings.
Deal Overview
| Parameter | Detail |
|---|---|
| Seller | Boya Biological Pharmacy Co., Ltd. (China) |
| Buyer | China Resources Double-Crane Pharmaceutical Co., Ltd. (State-owned enterprise under China Resources Group) |
| Target | Nanjing Xinbai Pharmaceutical Co., Ltd. |
| Transaction Value | RMB 235.5 million (~USD 34.4 million) |
| Equity Stake | 100% |
| Core Assets | Manufacturing facilities for lyophilized powders, small-volume injections, and oral solid dosage forms |
| Regulatory Status | All products compliant with China GMP standards |
Strategic Rationale & Portfolio Fit
- For CR Double-Crane: Strengthens its hospital drug franchise, which accounts for >65% of its revenue. Xinbai’s sterile injectables align with national priorities for high-quality generic parenterals.
- For Boya Biological: Streamlines operations by exiting non-core manufacturing assets to focus on biologics and specialty APIs.
- Market Position: Xinbai’s product portfolio serves Tier II/III hospitals across Jiangsu, Anhui, and Shandong provinces, complementing CR Double-Crane’s nationwide distribution network.
Financial & Operational Context
- Valuation Multiple: Implied EV/revenue multiple estimated at ~1.8x, reflecting modest margins typical of mature generic injectable producers.
- Integration Plan: Production lines to be retained; commercial operations migrated to CR Double-Crane’s sales force by Q1 2027.
- Synergies: Expected cost savings of RMB 20–30 million annually through procurement consolidation and logistics optimization.
Industry Backdrop
China’s generic injectables market remains under consolidation pressure as regulators enforce stringent quality standards and volume-based procurement (VBP) policies drive pricing discipline. State-owned enterprises like CR Double-Crane are actively acquiring compliant manufacturers to secure supply chain resilience and expand formulary breadth.
Forward‑Looking Statements
This brief summarizes a disclosed transaction. Closing is subject to customary regulatory approvals and may be influenced by China’s evolving pharmaceutical industrial policy.-Fineline Info & Tech